Nofazinlimab

诺法利单抗

Report date: 2022/01/18 17:53:18

Base Information

Drug NameNofazinlimab
Drug Alias NameCS-1003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCstone Pharmaceuticals
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCstone PharmaceuticalsEqrx IncCstone Pharmaceutical (Shanghai) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia